Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: Sr K who wrote (749)	9/16/2000 1:43:49 PM
From: Jack Doerr	Respond to of 756

Sr K, I could use some help if you are of a mind to. I recently took a fairly large loss when IVX took it's (what I consider to be) nefarious drop from around 50. I thought it would come back and in addition to maintaining a small position, bought 5 October 35 calls (@3 1/4). I know I won't get my loss back, but would like to get as much as possible (naturally). I am not very experienced in options. Do I just wait & try to exercise the option as high as possible, or is there some other possibly more profitable course I can take? An anticipatorial thanks, Jack

To: Sr K who wrote (749)	11/8/2000 10:26:36 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

No, I didn't go short. Lost interest completely. I've followed Frost since his days with Key Pharmaceuticals and am all too familiar with these types of swings. I think Ivax is probably a good long term buy, but wouldn't own much as a percentage of the portfolio because Frost's record isn't great, don't think he's proven that he can really manage a company for long term growth such as other generics BRL, AZA, TEVA or even MYL despite its recent setback. He has a tendency to rely on single drug home runs and when things fizzle so does the stock price until he can develop another. This doesn't make good predictable earnings growth. While Taxol-generic might work and make money for a while, according to Ivax's own investor relations and I quote from my conversation with him: "No one is going to make much money from these taxol drugs because of the competition." You can read my posts from way back on the subject -- some kinda crazy but some to the point. Good luck, Jackson